Millions of Medicare beneficiaries will gain access to weight-loss drugs for the first time under a temporary pilot program launching July 1. The Medicare GLP-1 Bridge program will cover popular GLP-1 medications like Wegovy and Zepbound, reducing out-of-pocket costs to $50 per month for eligible patients. The program, announced by the Centers for Medicare & Medicaid Services (CMS), marks a significant shift in Medicare policy, as the program has historically limited coverage of GLP-1 drugs to conditions like diabetes or cardiovascular disease.
Eligibility and Coverage Details
Eligible Medicare Part D enrollees can access the program, which runs through December 31, 2027. Patients must have a prior authorization request from their provider to qualify. The program covers drugs from Novo Nordisk and Eli Lilly, including Wegovy, Zepbound, and Foundayo. Without the program, these medications typically cost hundreds of dollars per month, even with insurance.
Policy and Long-Term Implications
The pilot program is the first time Medicare has covered GLP-1 drugs solely for weight loss. CMS Administrator Dr. Mehmet Oz emphasized the importance of expanding access to these treatments, which have been shown to help patients lose significant weight. However, the program's temporary nature raises questions about long-term access. After 2027, coverage could end unless CMS extends the program or Congress changes the law. Some experts suggest drug manufacturers may lower prices to match the $50 copay.
Patient Perspectives
For many seniors, the program could be life-changing. Mary Abrahamson, a 71-year-old from Washington, has been using a compounded version of a GLP-1 drug for weight loss but struggles with the cost. The $50 copay would allow her and her husband to afford the medications without financial strain, improving their quality of life.
Industry and Policy Context
Drugmakers have recently lowered out-of-pocket costs for GLP-1 medications, but many patients still face high expenses. The Medicare GLP-1 Bridge program aims to address this barrier. The program's success could influence future policy decisions regarding Medicare coverage for weight-loss treatments.